Lukasz Dutkiewicz, PhD has joined Ardigen as a Business Development Director of the Digital CRO division to support global expansion

March 24, 2022 – Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Lukasz Dutkiewicz, PhD has joined the company as Business Development Director of the Digital CRO division. He brings extensive knowledge and experience in business development and sales of complex IT services on international markets, which he gained at Hewlett Packard, IBM, and DXC Technology. Along with these credentials, Lukasz Dutkiewicz also has a strong research background in molecular dynamics and chemical physics.

Lukasz Dutkiewicz will be essential in accelerating Ardigen’s expansion into new markets and strengthening the brand’s position as a leader in AI enabled digital transformation in the field of drug discovery.

Prior to joining Ardigen, Lukasz Dutkiewicz was responsible for the development of strategic service business at DXC Technology in the EMEA region. Previously, he led IBM’s Long Term Signings Tiger Team for Poland, and managed HP’s outsourcing business unit in Poland. Additionally, Lukasz Dutkiewicz has 20+ years of experience in business transformation, outsourcing and large scale system integration. He has worked with major DXC, HP and IBM customers from various business sectors throughout EMEA and helped transform and align their IT with business. Lukasz Dutkiewicz earned a PhD in physics at the Jagiellonian University in Krakow, where he conducted research in the modeling of radiation processes on the surfaces of condensed gasses. Part of his research program was conducted at the University of Virginia, Rockefeller University, RWTH Aachen, and Risoe National Laboratory. He also holds an MBA from the University of Warsaw and a master’s degree in project management at George Washington University.

I am proud and excited to be joining Ardigen, which succeeded in synergizing the potential of its high performing biomedical research organization and latest AI technologies to set trends on the rapidly growing global market of AI drug discovery. I feel lucky and privileged to lead the team which brings Ardigen’s services to new markets, and enables more clients to benefit from the work of this fantastic expert team.  – comments Lukasz Dutkiewicz.

By joining Ardigen as Business Development Director of the Digital CRO division, Lukasz Dutkiewicz, PhD will strengthen the company’s position as a leader in the global AI field of Drug Discovery. This is an important step towards the implementation of the company’s long-term strategy and continues to provide strong revenue growth. – said Lukasz Nowak, Ardigen COO

About Ardigen & DigitalCRO unit

Ardigen is harnessing advanced AI methods for novel precision medicine. The company accelerates therapy development by designing immunity, decoding microbiomes, analyzing biomedical images and providing digital drug discovery services. Ardigen’s team is rooted in biology and has extensive expertise in bioinformatics, machine learning, and software engineering. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective precision therapies worldwide.

Ardigen Digital CRO business unit uniquely addresses key challenges of the modern drug discovery and development process. Trusted by many organizations, from cutting-edge startups to big pharmas, our success is founded on purpose-built and future-ready solutions.

More information at ardigen.com

Contact Details: 

Anna Klepacka
Marketing Manager

anna.klepacka@ardigen.com

Tags: Drug Discovery, Ardigen, Bioinformatic, Ai, Biotechnology, technology, Health